文献速递血栓与止血

靶向活化血小板的高亲和力重组凝血因子VIIa效力增强

Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets.
PubMed 文献 · J Thromb Haemost · 2019-10-14

本研究将重组凝血因子VIIa(rFVIIa)偶联至结合TLT-1的Fab片段,构建靶向活化血小板的PT-rFVIIa。体外实验显示PT-rFVIIa对活化血小板的催化效率提高,在最大活化血小板条件下 clot time 的半数有效浓度较rFVIIa低49倍;在F8-/-人TLT-1小鼠出血模型中,失血量的半数有效浓度低53倍,血友病A患者血液体外分析验证了该结果。

要点

  • PT-rFVIIa通过TLT-1靶向活化血小板,体外和体内效力均提高约50倍。
  • 最大活化血小板条件下的体外实验与小鼠体内数据相关,提示该条件适合评估血小板靶向止血策略。
  • 血友病A患者血液体外分析支持PT-rFVIIa的增效作用。

核心结论

  • 增加rFVIIa对活化血小板的亲和力可使体外和小鼠模型中的效力提高约50倍。

研究设计与样本

  • 将rFVIIa偶联至TLT-1结合Fab构建PT-rFVIIa;体外采用因子X激活试验和全血黏弹性检测,体内采用表达人TLT-1的F8-/-小鼠尾静脉横断模型。

主要发现

  • PT-rFVIIa与rFVIIa对组织因子结合的解离常数及组织因子依赖性因子X激活相似。
  • PT-rFVIIa在载有TLT-1的囊泡和活化血小板上的催化效率增加。
  • 在抗体诱导血友病A的正常人血液中,最大活化血小板条件下PT-rFVIIa使 clot time 的半数有效浓度较rFVIIa低49倍。
  • 在小鼠出血模型中,PT-rFVIIa使失血量的半数有效浓度低53倍。
  • 血友病A患者血液体外分析证实了正常人血液中获得的数据。

关键数值与推荐

  • 最大活化血小板条件下,PT-rFVIIa对 clot time 的半数有效浓度较rFVIIa低49倍。
  • 小鼠出血模型中,PT-rFVIIa对失血量的半数有效浓度较rFVIIa低53倍。

临床怎么用

  • PT-rFVIIa通过靶向活化血小板可大幅提高止血效力,支持进一步开发血小板靶向止血策略。
  • 评估血小板靶向止血概念时,采用最大活化血小板条件的体外试验可能与体内效果相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant factor VIIa (rFVIIa) enhances thrombin generation in a platelet-dependent manner; however, rFVIIa binds activated platelets with relatively low affinity. Triggering receptor expressed on myeloid cells (TREM)-like transcript (TLT)-1 is expressed exclusively on activated platelets. OBJECTIVE: To enhance the potency of rFVIIa via binding TLT-1. METHODS: Recombinant FVIIa was conjugated to a TLT-1 binding Fab. In vitro potency of this platelet-targeted rFVIIa (PT-rFVIIa) was evaluated using factor X activation assays and by measuring viscoelastic changes in whole blood. In vivo potency was evaluated using a tail vein transection model in F8-/- mice expressing human TLT-1. RESULTS: PT-rFVIIa and rFVIIa had similar dissociation constant values for tissue factor binding and similar tissue factor-dependent factor X activation. However, PT-rFVIIa had increased catalytic efficiency on TLT-1-loaded vesicles and activated platelets. The in vitro potency in normal human blood with antibody-induced hemophilia A was dependent on assay conditions used; with maximally activated platelets, the half maximal effective concentration for clot time for PT-rFVIIa was 49-fold lower compared with rFVIIa. In the murine bleeding model, a 53-fold lower half maximal effective concentration was observed for blood loss for PT-rFVIIa, supporting the relevance of the assay conditions with maximally activated platelets. In vitro analysis of blood from subjects with hemophilia A confirmed the data obtained with normal blood. CONCLUSIONS: Increasing the affinity of rFVIIa to activated platelets resulted in approximately 50-fold increased potency both in vitro and in the mouse model. The correlation of in vivo with in vitro data using maximally activated platelets supports that these assay conditions are relevant when evaluating platelet-targeted hemostatic concepts.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Enoksson M, Martin EJ, Holmberg H, et al. Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets. J Thromb Haemost. 2019. PMID: 31549480. doi:10.1111/jth.14644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。